BioWorld

June 21, 2007

Coley Stock Plunges As Pfizer Abandons NSCLC Program

Shares of Coley Pharmaceutical Group Inc. sank nearly 60 percent Wednesday on news that partner Pfizer Inc. has walked away from the investigation lung cancer drug PF-3512676, shelving two Phase III and two Phase II trials. (BioWorld Today) Read More

Panel: Communication Is Key For Working With The FDA

Renovo Licenses Juvista To Shire In Potential $825M Deal

Amsterdam Molecular Raises 50M In IPO For Gene Therapies

No Abstract Read More

Micromet Raising $25M Privately For Development Of Antibodies

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Wuxi Apptec insists it’s ‘not a Chinese military company’

BioWorld

Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...

Researchers hit back after colleagues removed from ADA meeting

BioWorld

Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an...